Netflix's continued popularity could undermine MoviePass' ability to acquire millions of subscribers.
A big rally driven by news of a favorable court ruling is unraveling now that all the details are known.
Is there a specific reason for Xunlei stock's rise on Tuesday?
Shares have seen increased volatility despite the company gaining its first-ever marketing approval recently.
Wall Street analyst cuts price target, so Spirit stock goes up. (Wait. What?)
Sometimes even a drop in profits still pleases investors.
The retailer continued to slide after a major investor said he would step down from its board.
Traders flee after the company announces that it is merging with a privately held drugmaker.
TransEnterix's stock keeps moving higher in the wake of the FDA clearing its novel robotic surgery device.
Shares are up, but that doesn't tell the whole story of TerraForm Power today.
The bitcoin revolution is even turning old "shorts" long.
Third-quarter results came in strong.
22nd Century Group may be ready to take flight as a result of the FDA's latest tobacco harm reduction initiative.
The patent litigation company jumped, then slumped, after a significant favorable judgment in its ongoing Apple case.
A key investor is leaving the department store chain's board.
NRD Capital, an Atlanta-based private equity firm, agreed to acquire struggling restaurant chain Ruby Tuesday for $2.40 per share -- here are the details.
In the wake of a challenging month, the company offered up some good news that kick-started shares today.
FDA approval for its lead drug candidate may have just become a bit more uncertain.
Positive phase 3 data for Cabometyx in liver cancer sends shares of the biotech higher.
An analyst sees the company's weak growth outlook as a major problem for the stock.
Shares of the upscale department store chain dipped after attempts to go private fizzled.
Shares soar after the company notches an important regulatory win.
The connected-home technology company is on roll in 2017, trading up roughly 200% year to date.
An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
The Chinese internet company was boosted on news regarding a subsidiary.
Here's how Sonus' third quarter was stronger than expected.
Uncertainty facing Hostess brands as it looks for a new CEO, as well as a recent downgrade, are dragging shares lower Friday -- here's what you need to know.
Positive phase 3 data for the biotech's irritable bowel syndrome drug, tenapanor, sends shares higher.
Amazon's moat may be expanding, and that's potentially bad news for MercadoLibre.
J. Jill's third-quarter update drops a bombshell on shareholders.
The freemium games specialist is up thanks to its new Taylor Swift app and an encouraging analyst upgrade.
An FDA rejection sends shares of the drugmaker lower.
After an incredible rise, shares of Helios and Matheson Analytics are taking a breather after the company filed a new 8-K with the SEC.
The Israel-based insurance software company posted big gains in September but still trades down roughly 5% year to date.
The used-car seller's "no-haggle" approach continues to resonate with car shoppers.
Shares of the women's-apparel retailer dove after getting an analyst downgrade.
The company has actually had fairly negative comparable store sales.
According to one analyst, advertisers may finally be embracing the recently IPO'd social-media company.
The stock soared on speculation that Apple will include many more of the chipmaker's products in the upcoming iPhone X smartphone.
The data storage expert's shares rose on positive comments from a couple of Wall Street analysts.
Dark clouds are gathering around this regional telecom, while its former networking infrastructure division moves on to greener pastures and longer customer lists.
The recent IPO is off to a solid start.
The biotech is raising cash after seeing its shares triple over the last month.
The networking specialist dropped after its fiscal second-quarter report. Here's what investors need to know.
Following news of Sears Canada's liquidation, Sears stock dipped once again.
The red-hot gene therapy start-up took a big step towards its first new drug application.
The semiconductor equipment company saw big gains last month and now trades at 10-year highs.
The industrial company got a big reward from the stock market for what seemed like no reason at all.
The retail juggernaut offered strong forward guidance and a huge new share repurchase program.
When the satellite-communications specialist filed a regulatory response document, investors were reminded that the company is facing some potential service-quality issues.